Share on StockTwits

Stock analysts at Leerink Swann decreased their target price on shares of HeartWare International (NASDAQ:HTWR) from $120.00 to $105.00 in a report issued on Friday. Leerink Swann’s price target would suggest a potential upside of 27.49% from the stock’s previous close.

Separately, analysts at Zacks upgraded shares of HeartWare International from a “neutral” rating to an “outperform” rating in a research note on Friday. They now have a $105.70 price target on the stock. One analyst has rated the stock with a sell rating and eight have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $107.14.

HeartWare International (NASDAQ:HTWR) traded down 2.20% on Friday, hitting $82.36. The stock had a trading volume of 192,814 shares. HeartWare International has a 52 week low of $69.31 and a 52 week high of $105.84. The stock’s 50-day moving average is $87.99 and its 200-day moving average is $92.05. The company’s market cap is $1.399 billion.

HeartWare International (NASDAQ:HTWR) last announced its earnings results on Thursday, July 31st. The company reported ($0.29) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.74) by $0.45. The company had revenue of $70.10 million for the quarter, compared to the consensus estimate of $67.01 million. Analysts expect that HeartWare International will post $-2.90 EPS for the current fiscal year.

Heartware International, Inc (NASDAQ:HTWR) develops and manufactures small implantable heart pumps, or ventricular assist devices, for the treatment of advanced heart failure.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.